Agence nationale de securite du medicament et des produits de sante (ANSM), France, has issued its final report citing 11 observations, in pursuance of the Good Manufacturing Practices (GMP) inspection at Gland Pharma’s material subsidiary -- Cenexi’s Fontenay manufacturing facility between December 09 to December 19, 2024.
Cenexi has undertaken a Corrective and Preventive Action Plan, with various appropriate measures, within a period ranging from 3 -12 months (varies for each observation), and the same has been accepted by ANSM. There will be no disruption in the manufacturing operations due to this final inspection report. Cenexi is committed to working closely with the ANSM to address the Observations and will provide further updates to the Exchanges as they become available.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1792.60 |
| Dr. Reddys Lab | 1279.20 |
| Cipla | 1395.00 |
| Zydus Lifesciences | 1089.40 |
| Lupin | 2300.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: